Jiashuo Chao

478 total citations · 1 hit paper
20 papers, 255 citations indexed

About

Jiashuo Chao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jiashuo Chao has authored 20 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 8 papers in Surgery. Recurrent topics in Jiashuo Chao's work include Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Mechanisms and Therapy (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Jiashuo Chao is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), Cancer Mechanisms and Therapy (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Jiashuo Chao collaborates with scholars based in China and United States. Jiashuo Chao's co-authors include Hongcheng Sun, Haitao Zhao, Senlin Zhao, Xiaobo Yang, Ziyu Xun, Longhao Zhang, Nan Zhang, Yunchao Wang, Xinmu Zhang and Yanyu Wang and has published in prestigious journals such as Nature Communications, Scientific Reports and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Jiashuo Chao

19 papers receiving 255 citations

Hit Papers

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor... 2024 2026 2025 2024 10 20 30 40
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
    2024 43 citations Nan Zhang, Yang Xu et al. Biomarker Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jiashuo Chao China 9 116 74 67 60 45 20 255
Aya El Helali Hong Kong 9 108 0.9× 94 1.3× 69 1.0× 34 0.6× 59 1.3× 34 288
Sunyoung S. Lee United States 10 99 0.9× 79 1.1× 112 1.7× 36 0.6× 58 1.3× 43 265
Zili Hu China 12 103 0.9× 76 1.0× 135 2.0× 70 1.2× 68 1.5× 35 316
Junjie Hu China 10 87 0.8× 96 1.3× 60 0.9× 84 1.4× 53 1.2× 19 302
Maria Aurelia Barbera Italy 9 134 1.2× 69 0.9× 104 1.6× 80 1.3× 70 1.6× 19 284
Chenhe Yi China 8 157 1.4× 119 1.6× 111 1.7× 90 1.5× 63 1.4× 16 354
Tunan Yu China 11 96 0.8× 112 1.5× 39 0.6× 130 2.2× 77 1.7× 27 326
Helena Degroote Belgium 11 66 0.6× 86 1.2× 91 1.4× 94 1.6× 80 1.8× 30 309
Vennis Lourdusamy United States 5 102 0.9× 51 0.7× 172 2.6× 72 1.2× 67 1.5× 16 320

Countries citing papers authored by Jiashuo Chao

Since Specialization
Citations

This map shows the geographic impact of Jiashuo Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiashuo Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiashuo Chao more than expected).

Fields of papers citing papers by Jiashuo Chao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiashuo Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiashuo Chao. The network helps show where Jiashuo Chao may publish in the future.

Co-authorship network of co-authors of Jiashuo Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Jiashuo Chao. A scholar is included among the top collaborators of Jiashuo Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiashuo Chao. Jiashuo Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chao, Jiashuo, Yuan Liang, Hao Wang, et al.. (2025). FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma. Nature Communications. 16(1). 9547–9547.
2.
Chao, Jiashuo, Hao Wang, Shuofeng Li, et al.. (2024). Effectiveness, safety, and biomarker analysis of lenvatinib plus toripalimab as chemo-free therapy in advanced intrahepatic cholangiocarcinoma: a real-world study. Cancer Immunology Immunotherapy. 73(12). 249–249. 3 indexed citations
3.
Zhu, Chengpei, Shanshan Wang, Yunchao Wang, et al.. (2024). Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer. Cancer Immunology Immunotherapy. 73(12). 240–240. 1 indexed citations
4.
Zhang, Nan, Yang Xu, Ziyu Xun, et al.. (2024). Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomarker Research. 12(1). 26–26. 43 indexed citations breakdown →
5.
Zhang, Chenchen, Shanshan Wang, Ziyu Xun, et al.. (2024). Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 12(6). e008686–e008686. 19 indexed citations
6.
Wang, Hao, Yuan Liang, Zheng Liu, et al.. (2024). POSTN+ cancer-associated fibroblasts determine the efficacy of immunotherapy in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 12(7). e008721–e008721. 41 indexed citations
7.
8.
Chao, Jiashuo, Shanshan Wang, Hao Wang, et al.. (2023). Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunology Immunotherapy. 72(11). 3717–3726. 14 indexed citations
9.
Wang, Yunchao, Nan Zhang, Jingnan Xue, et al.. (2023). Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC. Frontiers in Immunology. 14. 1084843–1084843. 8 indexed citations
10.
Ma, Cong, et al.. (2023). Targeting proteostasis network in osteoporosis: Pathological mechanisms and therapeutic implications. Ageing Research Reviews. 90. 102024–102024. 15 indexed citations
11.
Cong, Ning, Xinmu Zhang, Yanyu Wang, et al.. (2023). Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 118(5). 1461–1471. 14 indexed citations
12.
Zhang, Longhao, Jingnan Xue, Nan Zhang, et al.. (2023). The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.. PubMed. 13(8). 3582–3590. 2 indexed citations
13.
14.
Chao, Jiashuo, Qi Zhu, An Xiao, et al.. (2021). Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Frontiers in Oncology. 11. 667555–667555. 15 indexed citations
15.
Chao, Jiashuo, Qi Zhu, Guiming Chen, et al.. (2021). Combined analysis of imaging tumor capsule with imaging tumor size guides the width of resection margin for solitary hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international. 21(6). 551–558. 4 indexed citations
16.
Chao, Jiashuo, Senlin Zhao, & Hongcheng Sun. (2020). Dedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications.. PubMed. 12(5). 2099–2109. 31 indexed citations
17.
Zhu, Weifeng, Yan Deng, Xinjian Guo, et al.. (2019). MICA*049, not MICA*009, is associated with Behçet’s disease in a Chinese population. Scientific Reports. 9(1). 10856–10856. 4 indexed citations
18.
Chao, Jiashuo, Senlin Zhao, Yongbing Qian, et al.. (2019). Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation. World Journal of Gastroenterology. 25(37). 5630–5640. 4 indexed citations
19.
Li, Zhikun, Xiaodi Zheng, Jiashuo Chao, et al.. (2019). Development and validation of T‐ARMS‐PCR to detect CYP2C19*17 allele. Journal of Clinical Laboratory Analysis. 34(1). e23005–e23005. 8 indexed citations
20.
Chao, Jiashuo, et al.. (2018). Application of Single-Tube Tri-Primer ARMS-PCR to Detect the NFKB1 ATTG Insertion/Deletion Polymorphism. Genetic Testing and Molecular Biomarkers. 22(7). 443–447. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aya El Helali Breakdown of academic impact, for papers by Sunyoung S. Lee Breakdown of academic impact, for papers by Zili Hu Breakdown of academic impact, for papers by Junjie Hu Breakdown of academic impact, for papers by Maria Aurelia Barbera Breakdown of academic impact, for papers by Chenhe Yi Breakdown of academic impact, for papers by Tunan Yu Breakdown of academic impact, for papers by Helena Degroote Breakdown of academic impact, for papers by Vennis Lourdusamy
Rankless by CCL
2026